Immediate Management of Suspected Ceftriaxone-Induced Urticaria
This is most likely an IgE-mediated allergic reaction to ceftriaxone (Rocephin), and the patient should be treated immediately with antihistamines, monitored closely for progression to anaphylaxis, and have ceftriaxone permanently documented as an allergy. 1
Acute Management
Discontinue ceftriaxone immediately as the FDA label explicitly states that treatment must be stopped in cases of hypersensitivity reactions 1
Administer second-generation H1 antihistamines as first-line treatment for acute urticaria (cetirizine, loratadine, or fexofenadine preferred over first-generation due to fewer sedating effects) 2, 3
Monitor for anaphylaxis progression including respiratory distress, hypotension, laryngopharyngeal constriction, or cardiovascular compromise—if these develop, administer intramuscular epinephrine immediately 1, 4, 5
Consider short-course oral corticosteroids if minimal or no response to antihistamines within hours 2
Dexamethasone is unlikely the culprit given its mechanism of action and the temporal relationship, but ceftriaxone is a well-documented cause of urticaria and anaphylaxis 6, 7
Documentation and Future Management
Document this as a confirmed ceftriaxone allergy in the patient's medical record with specific details: urticarial reaction occurring immediately post-injection 8
Safe Beta-Lactam Alternatives
Penicillins with dissimilar R1 side chains can be safely administered without prior testing, as this was a non-anaphylactic immediate-type reaction to ceftriaxone 9
Other cephalosporins with dissimilar R1 side chains (such as cefazolin, cefuroxime, or cefepime) can be used, as cross-reactivity is mediated primarily by identical side chains rather than the beta-lactam ring 8, 9, 10
Avoid cephalosporins with identical R1 side chains to ceftriaxone as these carry higher cross-reactivity risk 4, 10
Carbapenems can be administered without testing or precautions, as cross-reactivity between ceftriaxone and carbapenems is exceedingly rare (0.87% overall) 8, 9
Aztreonam can be used safely as it shares no structural similarity with ceftriaxone 9
Allergy Evaluation Considerations
Formal allergy testing is NOT required for this non-anaphylactic cephalosporin reaction before administering alternative beta-lactams with dissimilar side chains 8
However, if future ceftriaxone use is absolutely necessary or if the patient requires multiple antibiotics:
Skin testing with ceftriaxone can be performed (epicutaneous at 90 mg/mL, intradermal at 1 mg/mL and 10 mg/mL) to confirm IgE-mediated hypersensitivity 8, 4
Penicillin skin testing followed by oral challenge has high negative predictive value (up to 95.2%) and can guide safe antibiotic selection 4
Basophil activation testing has variable sensitivity (38-75%) and is not routinely recommended 4
Critical Pitfalls to Avoid
Do not assume tolerance to one cephalosporin predicts tolerance to another—cefazolin tolerance does not predict ceftriaxone safety, as demonstrated by documented cases of anaphylaxis to ceftriaxone in patients who tolerated cefazolin 10
Do not perform penicillin allergy testing as a prerequisite for using alternative beta-lactams in this patient with isolated cephalosporin urticaria 8
Avoid rapid intravenous injection of any cephalosporin in the future, as this is an identified risk factor for severe reactions 6
Do not use long-term corticosteroids for management if urticaria persists beyond the acute phase 2